Emily Hsu

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study”.

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

The Lancet(2020)10.1016/s0140-6736(20)31187-9

N/A

11.9DataRank · unranked

1804 citations

Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein, Donna R. Rivera +95 more

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Annals of Oncology(2021)10.1016/j.annonc.2021.02.024

N/A

6.8DataRank · unranked

328 citations

Ali Raza Khaki, Trisha M. Wise‐Draper, Benjamin French, Conor Hennessy, Chih–Yuan Hsu +95 more

Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19

JAMA Oncology(2022)10.1001/jamaoncol.2022.5357

N/A

1.5DataRank · unranked

63 citations

Chris Labaki, Punita Grover, Joy Awosika, Shuchi Gulati, Chih–Yuan Hsu +95 more

A long-term fulvestrant eluting implant is safe, non-toxic, and reduces the risk of breast cancer in in vivo models.

Research Square(2023)10.21203/rs.3.rs-3459372/v1

N/A

0DataRank · unranked

0 citations

Elysia Roche, Pujan Desai, Nela Pawłowska, Diana Bauer, David Gingrich +5 more

Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant

Scientific Reports(2025)10.1038/s41598-024-77186-z

N/A

0DataRank · unranked

1 citations

Elysia Roche, Pujan Desai, Nela Pawłowska, Diana Bauer, David Gingrich +5 more